Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

Kinarus Therapeutics Holding AG / Key word(s): Patent Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 22.11.2022 / 07:00 CET/CEST MEDIA RELEASE

• Method-of-use-patent covers KIN001 in ophthalmic diseases
• Further strengthens already granted KIN001 US composition of matter patent

Basel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respiratory, and ophthalmic diseases, announced today the receipt of a Notice of Allowability from the United States Patent and Trademark Office (USPTO) for US Patent Application No. 16/500,504 “Methods of preventing or treating Ophthalmic Diseases “ covering its therapeutic candidate KIN001 in age-related macular degeneration (AMD).

The method of use patent is on top of granted US Patent No. 11285155 that protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. The composition of matter protection afforded by Patent No. 11285155 is irrespective of therapeutic indication.

Kinarus is currently developing KIN001 as an oral treatment for wet age-related macular degeneration, idiopathic pulmonary fibrosis, and Covid-19. 

Dr Alexander Bausch, Kinarus CEO, commented: “This USPTO allowance, together with the prior intellectual property secured by Kinarus in the US, EP, Australia, Eurasia, China, ARIPO and other countries, provides an even more secure IP protection for KIN001 in wet AMD and other retinal diseases. The positioning of KIN001 as an oral therapy in the ophthalmology space is unique. Our ambition is that KIN001 will be the first oral therapy used in combination with anti-VEGF therapies to stop progression of wet AMD and other retinal diseases in our aging population.”